187 related articles for article (PubMed ID: 26925127)
1. Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland.
Koczkodaj D; Zmorzyński S; Michalak-Wojnowska M; Wąsik-Szczepanek E; Filip AA
Arch Med Sci; 2016 Feb; 12(1):120-8. PubMed ID: 26925127
[TBL] [Abstract][Full Text] [Related]
2. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
3. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
[TBL] [Abstract][Full Text] [Related]
6. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
[TBL] [Abstract][Full Text] [Related]
7. NPM1 and FLT3 mutations in acute myeloid leukemia with normal karyotype: Indian perspective.
Sazawal S; Singh N; Jain S; Chhikara S; Chaubey R; Bhattacharyya J; Saikia KK; Mahapatra M; Saxena R
Indian J Pathol Microbiol; 2017; 60(3):355-359. PubMed ID: 28937371
[TBL] [Abstract][Full Text] [Related]
8. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
9. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype].
Su L; Li W; Cui JW; Tan YH; Yang Y; Liu XL; Yu P; Hu RP; Wang LL; Gao SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):571-5. PubMed ID: 23815900
[TBL] [Abstract][Full Text] [Related]
11. FLT3 internal tandem duplication and FLT3-D835 mutation in 80 AML patients categorized into cytogenetic risk groups.
Mały E; Przyborsk M; Nowak T; Nowak J; Januszkiewicz D
Postepy Hig Med Dosw (Online); 2010 Oct; 64():466-70. PubMed ID: 20966504
[TBL] [Abstract][Full Text] [Related]
12. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
13. FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia.
Mukda E; Pintaraks K; Sawangpanich R; Wiangnon S; Pakakasama S
Asian Pac J Cancer Prev; 2011; 12(7):1827-31. PubMed ID: 22126574
[TBL] [Abstract][Full Text] [Related]
14. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia - preliminary report.
Helbig G; Wozniczka K; Wieclawek A; Soja A; Bartkowska-Chrobok A; Kyrcz-Krzemien S
Contemp Oncol (Pozn); 2014; 18(4):241-5. PubMed ID: 25258581
[TBL] [Abstract][Full Text] [Related]
16. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population.
Suzuki R; Onizuka M; Kojima M; Shimada M; Okamura K; Fukagawa S; Tsuboi K; Kikuchi A; Kobayashi H; Shintani A; Ogawa Y; Kawada H; Hotta T; Ando K
Int J Hematol; 2007 Dec; 86(5):422-8. PubMed ID: 18192111
[TBL] [Abstract][Full Text] [Related]
18. Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML).
Dunna NR; Rajappa S; Digumarti R; Vure S; Kagita S; Damineni S; Rao VR; Yadav SK; Ravuri RR; Satti V
Asian Pac J Cancer Prev; 2010; 11(6):1811-6. PubMed ID: 21338238
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
20. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
